For example, a post hoc analysis of the randomized phase 3 MPACT trial (NCT00844649) found no association between vitamin D levels and overall survival (OS) in patients with pancreatic cancer.1 The MPACT study authors compared nab-paclitaxel and gemcitabine with gemcitabine alone in 861 patients with metastatic pancreatic cancer. Read more . . .
In recent years, plasma 25-hydroxyvitamin-D (vitamin D) levels have been implicated in the pathogenesis of pancreatic cancer, and several teams of investigators have attempted to clarify this association to determine whether vitamin D measurements have a prognostic role as a biomarker in this disease setting.